PrimaryLogo_Mango-05.png
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
June 06, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
May 28, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
May 23, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and...
PrimaryLogo_Mango-05.png
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
May 21, 2024 08:30 ET | Mangoceuticals, Inc.
Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”),...
PrimaryLogo_Mango-05.png
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
May 16, 2024 16:40 ET | Mangoceuticals, Inc.
Dallas, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
May 02, 2024 08:00 ET | Mangoceuticals, Inc.
Dallas, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
April 12, 2024 08:45 ET | Mangoceuticals, Inc.
Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico’s health governing agency, COFEPRIS Dallas, Texas, April ...
PrimaryLogo_Mango-05.png
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
March 12, 2024 09:00 ET | Mangoceuticals, Inc.
The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatment to the Telehealth Market Dallas, Texas, March 12, 2024 (GLOBE...
PrimaryLogo_Mango-05.png
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
February 20, 2024 09:00 ET | Mangoceuticals, Inc.
Newly developed clinic prescribing system will allow Doctors to prescribe MangoRx products from within practices and clinics Dallas, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc....
PrimaryLogo_Mango-05.png
MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY
February 13, 2024 08:00 ET | Mangoceuticals, Inc.
San Francisco Fans Nationwide Get Three Free Mangorx ED Pills Based on Sunday’s Game Point Difference Dallas, Texas, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX)...